Clearside Biomedical, Inc. (CLSD) financial statements (2022 and earlier)

Company profile

Business Address 900 NORTH POINT PARKWAY
ALPHARETTA, GA 30005
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:30,43617,28722,59540,90037,60083,600
Cash and cash equivalents30,43617,28722,5958,0439,22434,824
Short-term investments   32,83528,41648,807
Other undisclosed cash, cash equivalents, and short-term investments   22(40)(31)
Receivables10,000     
Prepaid expense9217221,1392,0491,445396
Other current assets7791091,48517116290
Other undisclosed current assets   (22)4031
Total current assets:42,13618,11825,21942,94439,20184,317
Noncurrent Assets
Operating lease, right-of-use asset369528656
Property, plant and equipment23841654179088594
Restricted cash and investments160260360360360360
Other noncurrent assets   264742
Total noncurrent assets:7671,2041,5571,1761,292496
TOTAL ASSETS:42,90319,32226,77644,12040,49384,813
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4,2533,5794,2109,79210,1005,385
Accounts payable9411,9971,2806,8695,3842,594
Accrued liabilities3,3121,5822,9302,9234,7162,791
Deferred revenue 5,0005,000
Debt 9911,6935563,200 
Deferred rent credit   128
Deferred revenue and credits199 
Other liabilities    2023
Other undisclosed current liabilities387373    
Total current liabilities:4,6409,94310,90310,47613,5195,408
Noncurrent Liabilities
Long-term debt and lease obligation2886164,7169,4194,8097,586
Long-term debt, excluding current maturities  3,8199,4194,8097,586
Operating lease, liability288616897
Liabilities, other than long-term debt   605750160
Deferred revenue and credits750160
Deferred rent credit   605
Other undisclosed noncurrent liabilities(288)(616)    
Total noncurrent liabilities:2886164,71610,0245,5597,746
Total liabilities:4,92810,55915,61920,50019,07813,154
Stockholders' equity
Stockholders' equity attributable to parent37,9758,76311,15723,62021,41571,659
Common stock605244322525
Additional paid in capital293,406264,578248,770230,475145,618136,892
Accumulated other comprehensive loss    (8)(13)
Accumulated deficit(255,491)(255,867)(237,657)(206,887)(124,220)(65,245)
Total stockholders' equity:37,9758,76311,15723,62021,41571,659
TOTAL LIABILITIES AND EQUITY:42,90319,32226,77644,12040,49384,813

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues29,5757,8942,17330 520
Revenue, net 520
Gross profit:29,5757,8942,17330 520
Operating expenses(30,202)(25,829)(32,477)(82,975)(58,753)(25,718)
Other undisclosed operating income    345 
Operating loss:(627)(17,935)(30,304)(82,945)(58,408)(25,198)
Nonoperating income (expense)1,003(275)(466)127(567)(684)
Other nonoperating income1,003     
Interest and debt expense998(147)(804)(791)(653)(287)
Income (loss) before gain (loss) on sale of properties:1,374(18,357)(31,574)(83,609)(59,628)(26,169)
Other undisclosed net income (loss)(1,750)147804791  
Net loss:(376)(18,210)(30,770)(82,818)(59,628)(26,169)
Other undisclosed net income attributable to parent752   653287
Net income (loss) available to common stockholders, diluted:376(18,210)(30,770)(82,818)(58,975)(25,882)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(376)(18,210)(30,770)(82,818)(59,628)(26,169)
Other comprehensive income (loss)    5(13)
Comprehensive loss:(376)(18,210)(30,770)(82,818)(59,623)(26,182)
Other undisclosed comprehensive income, net of tax, attributable to parent    653287
Comprehensive loss, net of tax, attributable to parent:(376)(18,210)(30,770)(82,818)(58,970)(25,895)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: